Background and Objectives: Acinetobacter species are responsible for a wide range of clinical complications in hospitalized patients. Antimicrobial treatment of clinical strains of Acinetobacter baumannii may be compromised due to multiple-drug resistance to -lactams. Aim of this study was to determine antibiotic resistance patterns and frequency of PER and VEB genes in A. baumannii isolates from hospitalized patients.
Most enzymes initially identified in 1980 were SHV and TEM. In addition to the main families, new families of ESBLs including PER, VEB, BEL, TLA, GES and BES have emerged globally (12). -lactamase production is known as the most important cause of resistance to -lactam antibiotics (10). In fact, the rapid transmission and dissemination of these enzymes have increased the prevalence of nosocomial infections. This study aimed at phenotypic investigation of ESBLs and molecular identification of PER and VEB resistance genes in A. baumannii isolates.
MATERIAL AND METHODS
In this study, 100 clinical samples from blood, urine, skin, wound, tracheal secretion and the respiratory tract were collected from hospitals in Qom province (Iran) between 2014 and 2015. MacConkey agar and Blood agar (Merck, Germany) were used for the primary isolation of bacteria. Bacteria were identified based on morphology ( (3, 5) . In recent years, the prevalence of bacterial resistance to common antibiotics has increased worldwide. Antibiotic resistance is considered as a major problem in the treatment and control of infections (6) . In addition, numerous studies have reported that the high rate of antibiotic resistance and subsequent increase in prevalence of hospital infections are due to indiscriminate use of antibiotics (7) . The high resistance of A. baumannii against antimicrobial agents may be intrinsic or due to genetic exchange of resistance factors. Majority of A. baumannii strains are resistant to ampicillin, amoxicillin-clavulanic acid, antistaphylococcal penicillin, expandedspectrum cephalosporins (except ceftazidime and cefepime), tetracycline, macrolides, rifampin and chloramphenicol. The resistance to non-carbapenem -lactamases is widely accompanied by overproduction of cephalosporinases.
The resistance to antimicrobial agents among clinical isolates may complicate the infection treatment process and have detrimental effects on disease outcomes and healthcare costs (8, 9) . Different types of -lactamases have been identified based on their characteristics and activities (10). Extended-spectrum betalactamases (ESBLs) are a group of enzymes that are able to hydrolyze -lactam antibiotics, including penicillin, expanded-spectrum cephalosporins, fourth-generation cephalosporins (cefepime) and aztreonam (11).
of DNA template, 10 pmol of each primer and double-distilled water to volume the solution. Thermal programs used for amplification of the PER gene was as follows: initial denaturation at 94 °C for 4 minutes, denaturation at 94 °C for 1 minute, annealing at 55 °C for 1 minute, extension at 72 °C for 1 minute and final extension at 72 °C for 5 minutes. Thermal program for amplification of the VEB gene was as follows: initial denaturation at 94 °C for 5 minutes, denaturation at 94 °C for 1 minute, annealing at 53 °C for 1 minute, extension at 72 °C for 1 minute and final extension at 72 °C for 5 minutes. The PCR products were subjected to direct double-stranded DNA sequencing (PCR Thermocycler, America). A 100 bp DNA ladder (PR901644, CinnaGene, Iran) was used as molecular marker for size of the amplicons. The amplified bands were visualized and photographed under UV ligh.
Moreover, 18% of A. baumannii isolates were only resistant to one antibiotic. Furthermore, 12% of the A. baumannii isolates were resistant to two antibiotics, while 70% of the isolates were resistant to three or more ( Table  2 ). The MIC against ceftazidime and cefepime was <128 µg/ml in 84% and 91% of strains, respectively. According to the results of CDT, 21% of the strains produced ESBL (Figure 1 DISCUSSION A. baumannii is an opportunistic pathogen and one of the main causes of nosocomial infections. Treatment is difficult, especially in the case of multi-drug resistant and ESBL-producing strains. In the past 30 years, several new -lactam antibiotics have been produced that are resistant to -lactamases. Nowadays, the prevalence of drug resistance is increasing due to inactivation of a wide range of -lactam antibiotics, especially third-generation cephalosporins and aztreonams. This has created numerous problems in the treatment of microbial infections. In this study, 72% of Acinetobacter isolates were identified as A. baumannii. The rest were A. lwoffii and other Acinetobacter species. These results are similar to study of Constantinou et al. which reported that 71.5% and 29% of isolates were A. baumannii and A. lwoffii, respectively (18). Ritand et al. also reported that among 4180 clinical isolates, 74.02% were A. baumannii and the rest were A. lwoffii and other Acinetobacter species (19) . with ESBL-producing bacteria, appropriate selection of antibiotics, identification of -lactamase-producing strains and preventing the spread of resistant bacteria in hospitals could help eliminate this problem.
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CONCLUSION
The increased resistance to expandedspectrum cephalosporins is of great clinical importance, especially for hospitalized patients. Identification of patients infected
